| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease.
|
Nat Genet
|
2011
|
13.25
|
|
2
|
A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.
|
N Engl J Med
|
2004
|
11.86
|
|
3
|
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy.
|
Lancet
|
2003
|
6.85
|
|
4
|
Prevalence of conventional risk factors in patients with coronary heart disease.
|
JAMA
|
2003
|
6.84
|
|
5
|
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
|
J Am Coll Cardiol
|
2011
|
6.35
|
|
6
|
Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents.
|
N Engl J Med
|
2007
|
5.37
|
|
7
|
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
|
Circulation
|
2011
|
5.09
|
|
8
|
Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial.
|
JAMA
|
2011
|
4.52
|
|
9
|
Radial artery bypass grafts have an increased occurrence of angiographically severe stenosis and occlusion compared with left internal mammary arteries and saphenous vein grafts.
|
Circulation
|
2004
|
4.13
|
|
10
|
Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial.
|
JAMA
|
2012
|
3.91
|
|
11
|
Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.
|
JAMA
|
2008
|
3.64
|
|
12
|
Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study.
|
Am J Epidemiol
|
2007
|
3.48
|
|
13
|
Bare metal stent restenosis is not a benign clinical entity.
|
Am Heart J
|
2006
|
3.39
|
|
14
|
Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial.
|
JAMA
|
2012
|
3.30
|
|
15
|
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial.
|
Circulation
|
2004
|
3.23
|
|
16
|
Multicenter validation of the diagnostic accuracy of a blood-based gene expression test for assessing obstructive coronary artery disease in nondiabetic patients.
|
Ann Intern Med
|
2010
|
3.17
|
|
17
|
Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial.
|
JAMA
|
2005
|
3.06
|
|
18
|
Stent thrombosis.
|
J Am Coll Cardiol
|
2010
|
2.86
|
|
19
|
Angiographic surrogate end points in drug-eluting stent trials: a systematic evaluation based on individual patient data from 11 randomized, controlled trials.
|
J Am Coll Cardiol
|
2008
|
2.54
|
|
20
|
A polymorphism in the protease-like domain of apolipoprotein(a) is associated with severe coronary artery disease.
|
Arterioscler Thromb Vasc Biol
|
2007
|
2.47
|
|
21
|
Association of gene variants with incident myocardial infarction in the Cardiovascular Health Study.
|
Arterioscler Thromb Vasc Biol
|
2007
|
2.36
|
|
22
|
Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction.
|
Am Heart J
|
2009
|
2.29
|
|
23
|
Percutaneous coronary intervention in patients with severe aortic stenosis: implications for transcatheter aortic valve replacement.
|
Circulation
|
2012
|
2.17
|
|
24
|
Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
|
JACC Cardiovasc Interv
|
2009
|
2.12
|
|
25
|
Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial.
|
JAMA
|
2006
|
2.03
|
|
26
|
Renal failure after percutaneous coronary intervention is associated with high mortality.
|
Catheter Cardiovasc Interv
|
2005
|
2.00
|
|
27
|
Usefulness of an elevated neutrophil to lymphocyte ratio in predicting long-term mortality after percutaneous coronary intervention.
|
Am J Cardiol
|
2006
|
2.00
|
|
28
|
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
|
Circulation
|
2011
|
1.99
|
|
29
|
Identification of four gene variants associated with myocardial infarction.
|
Am J Hum Genet
|
2005
|
1.89
|
|
30
|
Development of a network to test strategies in cardiovascular cell delivery: the NHLBI-sponsored Cardiovascular Cell Therapy Research Network (CCTRN).
|
J Cardiovasc Transl Res
|
2010
|
1.84
|
|
31
|
Percutaneous transvenous mitral annuloplasty: initial human experience with a novel coronary sinus implant device.
|
Circ Cardiovasc Interv
|
2009
|
1.77
|
|
32
|
Polymer-based paclitaxel-eluting stents reduce in-stent neointimal tissue proliferation: a serial volumetric intravascular ultrasound analysis from the TAXUS-IV trial.
|
J Am Coll Cardiol
|
2005
|
1.74
|
|
33
|
Five common gene variants identify elevated genetic risk for coronary heart disease.
|
Genet Med
|
2007
|
1.72
|
|
34
|
Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator.
|
Circ Arrhythm Electrophysiol
|
2012
|
1.66
|
|
35
|
Lack of benefit from intravenous platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment for percutaneous interventions of aortocoronary bypass grafts: a pooled analysis of five randomized clinical trials.
|
Circulation
|
2002
|
1.65
|
|
36
|
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
|
Catheter Cardiovasc Interv
|
2012
|
1.65
|
|
37
|
A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans.
|
Clin Pharmacol Ther
|
2002
|
1.63
|
|
38
|
Hypersensitivity reactions associated with endovascular devices.
|
Contact Dermatitis
|
2008
|
1.63
|
|
39
|
Emergency coronary artery bypass surgery in the contemporary percutaneous coronary intervention era.
|
Circulation
|
2002
|
1.60
|
|
40
|
Gene variants of VAMP8 and HNRPUL1 are associated with early-onset myocardial infarction.
|
Arterioscler Thromb Vasc Biol
|
2006
|
1.60
|
|
41
|
Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus: the TAXUS-IV trial.
|
J Am Coll Cardiol
|
2005
|
1.59
|
|
42
|
Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention.
|
Circulation
|
2002
|
1.58
|
|
43
|
Relation of inflammation and benefit of statins after percutaneous coronary interventions.
|
Circulation
|
2003
|
1.55
|
|
44
|
Predictors of revascularization method and long-term outcome of percutaneous coronary intervention or repeat coronary bypass surgery in patients with multivessel coronary disease and previous coronary bypass surgery.
|
Eur Heart J
|
2005
|
1.54
|
|
45
|
LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction.
|
Tex Heart Inst J
|
2010
|
1.52
|
|
46
|
Cause of death within 30 days of percutaneous coronary intervention in an era of mandatory outcome reporting.
|
J Am Coll Cardiol
|
2013
|
1.48
|
|
47
|
Enoxaparin in primary and facilitated percutaneous coronary intervention A formal prospective nonrandomized substudy of the FINESSE trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events).
|
JACC Cardiovasc Interv
|
2010
|
1.45
|
|
48
|
Arteriotomy closure device safety after percutaneous coronary intervention in the direct thrombin inhibitor era: a comparative study.
|
Catheter Cardiovasc Interv
|
2012
|
1.44
|
|
49
|
An integrated TAXUS IV, V, and VI intravascular ultrasound analysis of the predictors of edge restenosis after bare metal or paclitaxel-eluting stents.
|
Am J Cardiol
|
2008
|
1.44
|
|
50
|
Rescue percutaneous coronary intervention after failed fibrinolytic therapy: have expectations been met?
|
Am Heart J
|
2006
|
1.44
|
|
51
|
Influence of sex on long-term outcomes after percutaneous coronary intervention with the paclitaxel-eluting coronary stent: results of the "TAXUS Woman" analysis.
|
JACC Cardiovasc Interv
|
2010
|
1.43
|
|
52
|
Angiographic variables predict increased risk for adverse ischemic events after coronary stenting with glycoprotein IIb/IIIa inhibition: results from the TARGET trial.
|
J Am Coll Cardiol
|
2003
|
1.42
|
|
53
|
Drug-eluting stents: the beginning of the end of restenosis?
|
Cleve Clin J Med
|
2004
|
1.41
|
|
54
|
Clinical outcomes of drug-eluting versus bare-metal in-stent restenosis.
|
Catheter Cardiovasc Interv
|
2010
|
1.41
|
|
55
|
Impact of drug-eluting versus bare-metal stents on mortality in patients with anemia.
|
JACC Cardiovasc Interv
|
2009
|
1.40
|
|
56
|
The combination of enoxaparin, glycoprotein IIb/IIIa inhibitors and an early invasive approach among acute coronary syndrome patients.
|
J Invasive Cardiol
|
2004
|
1.40
|
|
57
|
Sirolimus-eluting coronary stents in octogenarians: a 1-year analysis of the worldwide e-SELECT Registry.
|
JACC Cardiovasc Interv
|
2011
|
1.39
|
|
58
|
Effectiveness and safety of bivalirudin during percutaneous coronary intervention in a single medical center.
|
Am J Cardiol
|
2005
|
1.39
|
|
59
|
Comparison of drug-eluting stents versus bare-metal stents for treating ST-segment elevation myocardial infarction.
|
JACC Cardiovasc Interv
|
2008
|
1.37
|
|
60
|
Development of a blood-based gene expression algorithm for assessment of obstructive coronary artery disease in non-diabetic patients.
|
BMC Med Genomics
|
2011
|
1.37
|
|
61
|
Benefit of facilitated percutaneous coronary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpercutaneous coronary intervention hospitals.
|
JACC Cardiovasc Interv
|
2009
|
1.35
|
|
62
|
A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex.
|
Circ Cardiovasc Genet
|
2012
|
1.35
|
|
63
|
Systemic elevations of free radical oxidation products of arachidonic acid are associated with angiographic evidence of coronary artery disease.
|
Free Radic Biol Med
|
2006
|
1.33
|
|
64
|
Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
|
J Am Coll Cardiol
|
2006
|
1.30
|
|
65
|
Intramyocardial injection of autologous bone marrow mononuclear cells for patients with chronic ischemic heart disease and left ventricular dysfunction (First Mononuclear Cells injected in the US [FOCUS]): Rationale and design.
|
Am Heart J
|
2010
|
1.28
|
|
66
|
2015 ACC/AHA/SCAI Focused Update on Primary Percutaneous Coronary Intervention for Patients With ST-Elevation Myocardial Infarction: An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention and the 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction.
|
J Am Coll Cardiol
|
2015
|
1.26
|
|
67
|
GOSR2 Lys67Arg is associated with hypertension in whites.
|
Am J Hypertens
|
2008
|
1.20
|
|
68
|
Two-year outcomes after sirolimus-eluting stent implantation: results from the Sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial.
|
J Am Coll Cardiol
|
2006
|
1.18
|
|
69
|
Analysis of 17,576 potentially functional SNPs in three case-control studies of myocardial infarction.
|
PLoS One
|
2008
|
1.17
|
|
70
|
Drug-eluting stents in the treatment of intermediate lesions: pooled analysis from four randomized trials.
|
J Am Coll Cardiol
|
2006
|
1.17
|
|
71
|
Outcomes with the paclitaxel-eluting stent in patients with acute coronary syndromes: analysis from the TAXUS-IV trial.
|
J Am Coll Cardiol
|
2005
|
1.15
|
|
72
|
Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention.
|
Am J Cardiol
|
2004
|
1.15
|
|
73
|
Impact of routine angiographic follow-up on the clinical benefits of paclitaxel-eluting stents: results from the TAXUS-IV trial.
|
J Am Coll Cardiol
|
2006
|
1.14
|
|
74
|
Development of coronary aneurysm after drug-eluting stent implantation.
|
Ann Intern Med
|
2007
|
1.14
|
|
75
|
Drug-eluting stent fracture and acute coronary syndrome.
|
Cardiovasc Revasc Med
|
2009
|
1.14
|
|
76
|
2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions.
|
Catheter Cardiovasc Interv
|
2011
|
1.13
|
|
77
|
Developing mechanistic insights into cardiovascular cell therapy: Cardiovascular Cell Therapy Research Network Biorepository Core Laboratory rationale.
|
Am Heart J
|
2011
|
1.13
|
|
78
|
Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials.
|
J Am Coll Cardiol
|
2008
|
1.11
|
|
79
|
Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation.
|
Circulation
|
2007
|
1.11
|
|
80
|
Association between CK-MB elevation after percutaneous or surgical revascularization and three-year mortality.
|
J Am Coll Cardiol
|
2002
|
1.10
|
|
81
|
Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease.
|
J Am Coll Cardiol
|
2005
|
1.09
|
|
82
|
Stent-assisted detachable coil embolization of pseudoaneurysms in the coronary circulation.
|
Catheter Cardiovasc Interv
|
2006
|
1.08
|
|
83
|
Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention.
|
Am J Cardiol
|
2005
|
1.06
|
|
84
|
Severe aortic stenosis and coronary artery disease--implications for management in the transcatheter aortic valve replacement era: a comprehensive review.
|
J Am Coll Cardiol
|
2013
|
1.05
|
|
85
|
In unstable angina or non-ST-segment acute coronary syndrome, should patients with multivessel coronary artery disease undergo multivessel or culprit-only stenting?
|
J Am Coll Cardiol
|
2007
|
1.04
|
|
86
|
Outcomes of paclitaxel-eluting stent implantation in patients with stenosis of the left anterior descending coronary artery.
|
J Am Coll Cardiol
|
2005
|
1.03
|
|
87
|
Impact of moderate renal insufficiency on restenosis and adverse clinical events after paclitaxel-eluting and bare metal stent implantation: results from the TAXUS-IV Trial.
|
Am Heart J
|
2005
|
1.01
|
|
88
|
Impact of coronary culprit lesion calcium in patients undergoing paclitaxel-eluting stent implantation (a TAXUS-IV sub study).
|
Am J Cardiol
|
2005
|
1.00
|
|
89
|
Thrombosis and drug-eluting stents: an objective appraisal.
|
J Am Coll Cardiol
|
2007
|
1.00
|
|
90
|
Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting.
|
J Am Coll Cardiol
|
2002
|
0.98
|
|
91
|
Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial.
|
J Cardiovasc Transl Res
|
2012
|
0.97
|
|
92
|
Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention.
|
Am J Cardiol
|
2004
|
0.96
|
|
93
|
Cellular, but not direct, adenoviral delivery of vascular endothelial growth factor results in improved left ventricular function and neovascularization in dilated ischemic cardiomyopathy.
|
J Am Coll Cardiol
|
2004
|
0.94
|
|
94
|
Impact of obesity on revascularization and restenosis rates after bare-metal and drug-eluting stent implantation (from the TAXUS-IV trial).
|
Am J Cardiol
|
2005
|
0.94
|
|
95
|
Comparison of percutaneous versus surgical revascularization of severe unprotected left main coronary stenosis in matched patients.
|
Am J Cardiol
|
2007
|
0.93
|
|
96
|
The clinical impact of routine angiographic follow-up in randomized trials of drug-eluting stents: a critical assessment of "oculostenotic" reintervention in patients with intermediate lesions.
|
JACC Cardiovasc Interv
|
2010
|
0.93
|
|
97
|
The transcription factor GATA-2 does not associate with angiographic coronary artery disease in the Ottawa Heart Genomics and Cleveland Clinic GeneBank Studies.
|
Hum Genet
|
2009
|
0.92
|
|
98
|
Outcomes in African Americans and whites after percutaneous coronary intervention.
|
Am J Med
|
2005
|
0.90
|
|
99
|
Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality.
|
J Am Coll Cardiol
|
2008
|
0.89
|
|
100
|
A meta-analysis of randomized trials of rescue percutaneous coronary intervention after failed fibrinolysis.
|
Am J Cardiol
|
2006
|
0.89
|
|
101
|
Benefits of direct angioplasty for women and men with acute myocardial infarction: results of the Global Use of Strategies to Open Occluded Arteries in Acute Coronary Syndromes Angioplasty (GUSTO II-B) Angioplasty Substudy.
|
Am Heart J
|
2004
|
0.89
|
|
102
|
Cell tracking and the development of cell-based therapies: a view from the Cardiovascular Cell Therapy Research Network.
|
JACC Cardiovasc Imaging
|
2012
|
0.89
|
|
103
|
Characterization of post-operative risk associated with prior drug-eluting stent use.
|
JACC Cardiovasc Interv
|
2009
|
0.89
|
|
104
|
Mortality benefit of beta-blockade after successful elective percutaneous coronary intervention.
|
J Am Coll Cardiol
|
2002
|
0.89
|
|
105
|
Bringing cardiovascular cell-based therapy to clinical application: perspectives based on a National Heart, Lung, and Blood Institute Cell Therapy Working Group meeting.
|
Am Heart J
|
2007
|
0.89
|
|
106
|
Revascularization for unprotected left main disease: evolution of the evidence basis to redefine treatment standards.
|
J Am Coll Cardiol
|
2009
|
0.89
|
|
107
|
Racial differences in long-term outcomes after percutaneous coronary intervention with paclitaxel-eluting coronary stents.
|
J Interv Cardiol
|
2012
|
0.88
|
|
108
|
Meta-analysis of the effects of paclitaxel-eluting stents versus bare metal stents on volumetric intravascular ultrasound in patients with versus without diabetes mellitus.
|
Am J Cardiol
|
2008
|
0.86
|
|
109
|
A critical analysis of clinical outcomes reported in stem cell trials for acute myocardial infarction: some thoughts for design of future trials.
|
Curr Atheroscler Rep
|
2013
|
0.86
|
|
110
|
Eroding the denominator: the incomplete story of door-to-balloon time reporting.
|
J Am Coll Cardiol
|
2012
|
0.85
|
|
111
|
Autologous cell transplantation for the treatment of damaged myocardium.
|
Prog Cardiovasc Dis
|
2002
|
0.85
|
|
112
|
Frequency of coronary artery bypass grafting following implantation of a paclitaxel-eluting or a bare-metal stent into a single coronary artery.
|
Am J Cardiol
|
2008
|
0.84
|
|
113
|
Impact of female sex on outcome after percutaneous coronary intervention.
|
Am Heart J
|
2004
|
0.84
|
|
114
|
Presence of carotid and peripheral arterial disease in patients with left main disease.
|
Am J Cardiol
|
2007
|
0.84
|
|
115
|
Preprocedural white blood cell count and death after percutaneous coronary intervention.
|
Am Heart J
|
2003
|
0.83
|
|
116
|
Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction.
|
Am J Cardiol
|
2002
|
0.83
|
|
117
|
Abciximab-facilitated percutaneous coronary intervention and long-term survival--a prospective single-center registry.
|
Eur Heart J
|
2003
|
0.83
|
|
118
|
Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial.
|
Cell Transplant
|
2015
|
0.83
|
|
119
|
Influence of gender on long-term mortality in patients presenting with non-ST-elevation acute coronary syndromes undergoing percutaneous coronary intervention.
|
Am J Cardiol
|
2012
|
0.82
|
|
120
|
Effect of the polymer-based, paclitaxel-eluting TAXUS Express stent on vascular tissue responses: a volumetric intravascular ultrasound integrated analysis from the TAXUS IV, V, and VI trials.
|
Eur Heart J
|
2007
|
0.82
|
|
121
|
Predictive models for short- and long-term adverse outcomes following discharge in a contemporary population with acute coronary syndromes.
|
Am J Cardiovasc Dis
|
2013
|
0.81
|
|
122
|
Downstream coronary effects of drug-eluting stents.
|
Am Heart J
|
2011
|
0.80
|
|
123
|
The Weasel Clause: Excluding Patients From Door-to-Balloon Analyses.
|
J Am Coll Cardiol
|
2010
|
0.80
|
|
124
|
Impact of drug-eluting stents on distal vessels.
|
Circ Cardiovasc Interv
|
2012
|
0.80
|
|
125
|
Effect of catheter-based iridium-192 gamma brachytherapy on the added risk of restenosis from diabetes mellitus after intervention for in-stent restenosis (subanalysis of the GAMMA I Randomized Trial).
|
Am J Cardiol
|
2002
|
0.80
|
|
126
|
Serial intravascular ultrasound analysis of stent strut distribution and fracture: an integrated analysis of the taxus IV, V, and VI trials.
|
J Invasive Cardiol
|
2014
|
0.80
|
|
127
|
Dynamic change in mitral annular area and motion during percutaneous mitral annuloplasty for ischemic mitral regurgitation: preliminary animal study with real-time 3-dimensional echocardiography.
|
J Am Soc Echocardiogr
|
2007
|
0.79
|
|
128
|
Long-term paclitaxel-eluting stent outcomes in elderly patients.
|
Circ Cardiovasc Interv
|
2009
|
0.79
|
|
129
|
Safety and efficacy of overlapping sirolimus-eluting versus paclitaxel-eluting stents.
|
Am Heart J
|
2008
|
0.79
|
|
130
|
Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program.
|
JACC Cardiovasc Interv
|
2011
|
0.78
|
|
131
|
Plaque vulnerability, plaque rupture, and acute coronary syndromes: (multi)-focal manifestation of a systemic disease process.
|
Circulation
|
2002
|
0.78
|
|
132
|
Outcomes of culprit versus multivessel PCI in patients with multivessel coronary artery disease presenting with ST-elevation myocardial infarction complicated by shock.
|
J Invasive Cardiol
|
2013
|
0.78
|
|
133
|
A randomized trial of 5 versus 7 French guiding catheters for transfemoral percutaneous coronary stent implantation.
|
J Interv Cardiol
|
2007
|
0.78
|
|
134
|
Safety of "bridging" with eptifibatide for patients with coronary stents before cardiac and non-cardiac surgery.
|
Am J Cardiol
|
2012
|
0.78
|
|
135
|
Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial.
|
J Am Coll Cardiol
|
2002
|
0.78
|
|
136
|
ACCF/AHA/SCAI 2007 update of the clinical competence statement on cardiac interventional procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (writing Committee to Update the 1998 Clinical Competence Statement on Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures).
|
J Am Coll Cardiol
|
2007
|
0.78
|
|
137
|
Recapturing the magic: revisiting the pleiotropic effects of statins in percutaneous coronary revascularization.
|
J Am Coll Cardiol
|
2009
|
0.78
|
|
138
|
Meta-analysis of angiographic versus intravascular ultrasound parameters of drug-eluting stent efficacy (from TAXUS IV, V, and VI).
|
Am J Cardiol
|
2007
|
0.78
|
|
139
|
ACCF/AHA/SCAI 2007 update of the Clinical Competence Statement on Cardiac Interventional Procedures: a report of the American College of Cardiology Foundation/American Heart Association/American College of Physicians Task Force on Clinical Competence and Training (Writing Committee to Update the 1998 Clinical Competence Statement on Recommendations for the Assessment and Maintenance of Proficiency in Coronary Interventional Procedures).
|
Circulation
|
2007
|
0.78
|
|
140
|
Impact of platelet glycoprotein IIb/IIIa Inhibition on the paclitaxel-eluting stent in patients with stable or unstable angina pectoris or provocable myocardial ischemia (a TAXUS IV substudy).
|
Am J Cardiol
|
2005
|
0.77
|
|
141
|
Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis.
|
Catheter Cardiovasc Interv
|
2010
|
0.77
|
|
142
|
Effect of prolonged thienopyridine use after drug-eluting stent implantation (from the TAXUS landmark trials data).
|
Am J Cardiol
|
2008
|
0.77
|
|
143
|
Polymorphisms and noncardioembolic stroke in three case-control studies.
|
Cerebrovasc Dis
|
2011
|
0.76
|
|
144
|
The safety of a bivalirudin-based approach in patients undergoing rotational atherectomy.
|
J Invasive Cardiol
|
2007
|
0.76
|
|
145
|
Stent choice and the hidden consequences of cost savings.
|
Nat Rev Cardiol
|
2012
|
0.76
|
|
146
|
Drug-eluting versus bare-metal stents for treating saphenous vein grafts.
|
Am Heart J
|
2009
|
0.76
|
|
147
|
The interaction of vascular inflammation and chronic kidney disease for the prediction of long-term death after percutaneous coronary intervention.
|
Am Heart J
|
2005
|
0.76
|
|
148
|
Use of platelet glycoprotein IIb/IIIa inhibitors in saphenous vein graft percutaneous coronary intervention and clinical outcomes.
|
Am J Cardiol
|
2006
|
0.76
|
|
149
|
Radial-artery coronary bypass grafts.
|
N Engl J Med
|
2005
|
0.76
|
|
150
|
Coronary revascularization for patients with diabetes: updated data favor coronary artery bypass grafting.
|
J Am Coll Cardiol
|
2013
|
0.75
|
|
151
|
Restenosis, statistics, and reasonable inferences.
|
J Am Coll Cardiol
|
2006
|
0.75
|
|
152
|
"Crying fire in a theater" or a "confirmatory sighting?".
|
J Am Coll Cardiol
|
2007
|
0.75
|
|
153
|
A generation 2.5 drug-eluting stent?
|
JACC Cardiovasc Interv
|
2009
|
0.75
|
|
154
|
Refining the art and science of coronary stenting.
|
N Engl J Med
|
2009
|
0.75
|
|
155
|
Transradial catheterization: the road less traveled.
|
J Invasive Cardiol
|
2004
|
0.75
|
|
156
|
Percutaneous left main invention an evolving perspective.
|
JACC Cardiovasc Interv
|
2010
|
0.75
|
|
157
|
Current Perspectives and Practices on Chronic Total Occlusion Percutaneous Coronary Interventions.
|
J Invasive Cardiol
|
2017
|
0.75
|
|
158
|
Outcomes of cardiac catheterization and percutaneous coronary intervention for in-hospital ventricular tachycardia or fibrillation cardiac arrest.
|
Catheter Cardiovasc Interv
|
2011
|
0.75
|
|
159
|
Periprocedural myonecrosis: from a laboratory anomaly to a sentinel of risk.
|
Ital Heart J
|
2003
|
0.75
|
|
160
|
Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency.
|
Am J Cardiol
|
2002
|
0.75
|
|
161
|
Revisiting optimal anticoagulation with unfractionated heparin during coronary stent implantation.
|
Am J Cardiol
|
2003
|
0.75
|
|
162
|
Understanding and minimizing late thrombosis of drug-eluting stents.
|
Cleve Clin J Med
|
2007
|
0.75
|
|
163
|
Long term follow-up of drug eluting versus bare metal stents in the treatment of saphenous vein graft lesions.
|
Catheter Cardiovasc Interv
|
2013
|
0.75
|
|
164
|
Use of PercuSurge GuardWire in native coronary arteries during acute myocardial infarction.
|
J Invasive Cardiol
|
2004
|
0.75
|
|
165
|
Systemic Pharmacokinetics of Everolimus Eluted From the Absorb Bioresorbable Vascular Scaffold: An ABSORB III Substudy.
|
J Am Coll Cardiol
|
2015
|
0.75
|
|
166
|
Percutaneous coronary intervention of the left main coronary artery in a patient with extrinsic compression caused by massive pulmonary artery enlargement.
|
J Thorac Cardiovasc Surg
|
2012
|
0.75
|
|
167
|
Angiographic lesion severity and subsequent myocardial infarction.
|
Am J Cardiol
|
2012
|
0.75
|
|
168
|
Effect of uncoated stenting versus balloon angioplasty alone of long coronary (>20 mm) versus shorter narrowings on one-year event-free survival.
|
Am J Cardiol
|
2003
|
0.75
|
|
169
|
Integrated analysis of medically treated diabetic patients in the TAXUS(R) program: benefits across stent platforms, paclitaxel release formulations, and diabetic treatments.
|
EuroIntervention
|
2006
|
0.75
|
|
170
|
Relation of myocardial perfusion to mortality after primary percutaneous coronary intervention.
|
Am J Cardiol
|
2005
|
0.75
|
|
171
|
Stenting for ST-segment elevation myocardial infarction is associated with less neointimal hyperplasia in the pooled IVUS analysis from HORIZONS-AMI and the TAXUS IV and V and ATLAS workhorse, long lesion, and direct stent studies.
|
Coron Artery Dis
|
2014
|
0.75
|
|
172
|
Impaired myocardial perfusion score and inflammatory markers in patients undergoing primary angioplasty for acute myocardial infarction.
|
Arch Cardiol Mex
|
2007
|
0.75
|
|
173
|
Relation of C-reactive protein level and long-term risk of death or myocardial infarction following percutaneous coronary intervention with a sirolimus-eluting stent.
|
Am J Cardiol
|
2006
|
0.75
|
|
174
|
Impact of diabetes on long-term mortality following multivessel percutaneous interventions: an insight into optimal statistical analysis.
|
Int J Cardiol
|
2012
|
0.75
|
|
175
|
Preprocedural statin use is associated with a reduced hazard of postprocedural myonecrosis in patients undergoing rotational atherectomy--a propensity-adjusted analysis.
|
Am Heart J
|
2006
|
0.75
|
|
176
|
Influence of stent length to lesion length ratio on angiographic and clinical outcomes after implantation of bare metal and drug-eluting stents (the TAXUS-IV Study).
|
Am J Cardiol
|
2005
|
0.75
|
|
177
|
Impact of in-stent minimal lumen area at 9 months poststent implantation on 3-year target lesion revascularization-free survival: a serial intravascular ultrasound analysis from the TAXUS IV, V, and VI trials.
|
Circ Cardiovasc Interv
|
2008
|
0.75
|
|
178
|
Impact of mild or moderate renal insufficiency on the intravascular ultrasonic analysis of chronic vascular response to paclitaxel-eluting and bare-metal stents (from the TAXUS IV, V, and VI trials).
|
Am J Cardiol
|
2008
|
0.75
|
|
179
|
The Time-Varying Risk of Cardiovascular and Noncardiovascular Readmissions Early After Acute Myocardial Infarction.
|
J Am Coll Cardiol
|
2017
|
0.75
|
|
180
|
Vascular responses to the multiple overlapped paclitaxel-eluting stents for the treatment of bare-metal in-stent restenotic lesions: angiographic and intravascular ultrasound analysis from the TAXUS-V ISR trial.
|
Cardiovasc Revasc Med
|
2010
|
0.75
|
|
181
|
Clopidogrel is associated with better in-hospital and 30-day outcomes than ticlopidine after coronary stenting.
|
Can J Cardiol
|
2003
|
0.75
|
|
182
|
Safe and efficacious use of bivalirudin for percutaneous coronary intervention with adjunctive platelet glycoprotein IIb/IIIa receptor inhibition.
|
Am J Cardiol
|
2003
|
0.75
|
|
183
|
Prognostic significance of creatine kinase-MB elevation after percutaneous coronary intervention in patients with chronic renal dysfunction.
|
Am Heart J
|
2002
|
0.75
|
|
184
|
Comparison of outcomes of unprotected left main versus multivessel coronary artery interventions.
|
Am J Cardiol
|
2011
|
0.75
|
|
185
|
GuardWire emboli protection device is associated with improved myocardial perfusion grade in saphenous vein graft intervention.
|
Am Heart J
|
2004
|
0.75
|
|
186
|
Percutaneous coronary revascularization in coronary artery disease: lessons from a single center experience.
|
Catheter Cardiovasc Interv
|
2012
|
0.75
|
|
187
|
Glycoprotein IIb-IIIa inhibition with abciximab and postprocedural risk assessment: lessons from the evaluation of platelet IIb/IIIa inhibitor for stenting trial and implication for ad hoc use of glycoprotein IIb-IIIa antagonists.
|
Am Heart J
|
2002
|
0.75
|